Study 0015 (NCT00107952) compares the safety and effectiveness of an investigational drug,
telavancin, with vancomycin for the treatment of hospital-acquired pneumonia.
- Clinical signs and symptoms consistent with pneumonia acquired after at least 48
hours of continuous stay in an inpatient acute or chronic care facility or acquired
within 7 days after being discharged from a hospitalization of greater than or equal
to 3 days duration.
- Received more than 24 hours of potentially effective systemic (IV, IM or PO)
antibiotic therapy for Gram-positive pneumonia immediately prior to randomization